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ABSTRACT: Heterogeneity of polymeric carriers is one of the most
elusive obstacles in the development of nonviral gene delivery systems,
concealing interaction mechanisms and limiting the use of structure−
activity relationship studies. In this report, novel sequence-defined
polyaminoamides, prepared by solid-phase assisted synthesis, were
used to establish first structure−activity relationships for polymer-
based plasmid DNA delivery. By combining a cationic building block
with hydrophobic modifications and bioreversible disulfide cross-
linking sites, transfection polymers with tailored lytic and DNA
binding properties were designed. These polymers demonstrated clear
correlation between structure and performance in lysis and DNA
binding assays. In vitro studies showed negligible toxicity and highly
efficient gene transfer, demonstrating the potential of this platform in
the fast, combinatorial development of new transfection polymers.
■ INTRODUCTION
Gene therapy is a promising therapeutic strategy based on the
concept of treating a disease at its molecular point of origin.1 By
introducing new genetic material into target cells, deficient
genes can be replaced by functional copies, new genes can be
introduced into the cell, or existing expression patterns can be
altered. These properties make gene therapy a potentially useful
tool for treating diseases, which cannot be remedied by more
conventional means.2−4 Broad clinical use has not been
achieved so far, due to the specific hurdles of delivering nucleic
acids (NA) to the target cells. While recombinant viral delivery
vectors are quite effectively used in clinical studies and
demonstrate unequaled delivery efficiency, there are major
concerns about their clinical safety with special emphasis on
risks like insertional mutagenesis, immunogenicity, and
inflammatory potential.5,6 Polymeric delivery systems as
alternatives allow faster development circles, easy modification,
and increased loading capacity, and are in general better
tolerated by the immune system. However, despite significant
progress in the development of polymeric carriers, they are still
characterized by a rather low efficiency and their potential is far
from being fully exploited.
The low efficiency of nonviral vectors stems from the
numerous extracellular and intracellular barriers entrapping or
destroying significant amounts of the payload before entering
the cell.7 As most of the carrier systems enter cells by
endosomal uptake routes, one of the biggest barriers is the
successful escape out of the endosome. Viral delivery systems
use a sophisticated protein machinery to interact with the
endosomal microenvironment with the aim to escape the
endosome.8 The hemagglutinin, a glycoprotein of influenza
virus A, for example, is triggered by the acidification of the
endosome, causing a conformational change, which results in
the fusion between viral and host cell membranes and
penetration of the viral genome into the cytosol.9 Polymeric
systems employing complex structural changes like this have
not been constructed up to now, but the described systems
exploit similar endosomal escape characteristics. Polymeric
carriers like polyethylenimine (PEI) or polyamidoamine
(PAMAM) dendrimers utilize their high intrinsic buffer
capacity to cause an osmotic burst of the endosome.10 The
required high endosomal concentration of these polymers
necessitates the use of a large excess or a high Mw species to
achieve an acceptable rate of success. To further improve their
efficiencies, different strategies were introduced, e.g., the
incorporation of membrane disrupting peptides11,12 into the
delivery system, or the use of hydrophobic modifications. These
modifications increase the interactions with cellular mem-
branes13,14 and have also been used for stabilization and
modulation of polymer nanoaggregate formation in vitro and in
vitro.15,16 Although all of these approaches have their
advantages, they are still limited by the inherent heterogeneity
of the polymeric carriers, which conceals precise structure−
activity relationships. This is especially important for
programmed, bioresponsive delivery systems, which consist of
multiple domains including elements for targeting, shielding,
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and release of the payload.17 Increased molecular precision in
the assembly of these systems would allow the design of even
more complex systems. Hartman et al.18 demonstrated recently
the synthesis of linear polyaminoamides (PAAs) using solid-
phase assisted synthesis. Adopting this approach for combina-
torial polymer development, although with a different chemical
strategy, gave access to highly defined and functionalized
polymers. We recently described the synthesis of protected
polyamino acid building blocks for fmoc solid-phase assisted
polymer synthesis,19 and their application in the construction of
a modular polymeric platform for plasmid DNA (pDNA) and
siRNA delivery was reported in a short communication.20 The
current paper describes in more detail the design and evaluation
of 26 modular constructed PAAs for pDNA delivery. Polymers
with tailored complexation capabilities and lytic activity were
constructed by combining different elements for DNA binding,
pH-triggered endosomal escape, and bioresponsive stabiliza-
tion. Correlation of the results of pDNA complexation and pH-
dependent lytic activity assays with their in vitro pDNA
transfection potential allowed establishment of first structure−
activity relationships for this new class of transfection reagents.
■ MATERIALS AND METHODS
Materials. Fmoc-amino acids and resins (base resins and
preloaded resins) were purchased from IRIS Biotech,
Marktredwitz, and Novabiochem GmbH, Darmstadt. PyBOP
was bought from MultiSynTech GmbH, Witten. DCM, DMF,
MeOH, and THF were obtained from Merck and distilled
before use. Water was used as purified, deionized water. LPEI
and fmoc-Stp(boc)3-OH were synthesized as described.
19,21
DMSO, EtOH, ACN, deuterated solvents, and MTT bromide
were obtained from Sigma-Aldrich (Munich, Germany).
Plasmid pEGFPLuc (encoding a fusion of enhanced green
fluorescent protein (EGFP) and Photinus pyralis luciferase
under control of the CMV promoter) was produced with the
Qiagen Plasmid Giga Kit (Qiagen, Hilden, Germany) according
to the manufacturer recommendations. Cell culture media,
antibiotics, and fetal calf serum were purchased from Invitrogen
(Karlsruhe, Germany). Luciferase cell culture lysis buffer and D-
luciferin sodium salt were obtained from Promega (Mannheim,
Germany). All polymer characterization data can be found in
the Supporting Information.
Synthesis of i-Shapes with two FAs: HO-K-Stp1-K-FA2.
After swelling of fmoc-Lys(boc)-Wang resin (0.05−0.20 mmol)
in DCM (30 min) and cleavage of the fmoc protecting group
(20% piperidine in DMF, twice), 4 equiv of a solution of fmoc-
Stp(boc)3-OH in DMF, DIPEA (8 equiv), and PyBOP/HOBt
(4 equiv) were added to the resin, and the vessel was agitated
until Kaiser test indicated complete conversion (30 min). The
reaction solvent was drained, and the resin was washed five
times with DMF. To couple two fatty acids to the N-terminus
of the PAA, fmoc-Lys(fmoc)-OH was incorporated before the
coupling of the fatty acid. To cap residual, unreacted primary
amino groups before introduction of the fatty acid, the resin
was acetylated using 5 equiv of acetic anhydride and 10 equiv of
DIPEA, before subsequent removal of the fmoc protecting
group. The resin was washed three times with DMF followed
by three DCM washes after removal of the fmoc protecting
group. Ten equivalents of the fatty acid were dissolved in DCM
and were added to the resin together with 10 equiv of PyBOP/
HOBt and 20 equiv of DIPEA in the smallest possible amount
of DMF. The mixture was agitated until Kaiser test indicated
complete conversion (normally 30 min). After completion of
the reaction, the resin was washed with DMF, DCM, and n-
hexane and dried for 12 h over KOH in vacuo.
Synthesis of i-Shapes with Two Coupling Domains:
HO-C-Stp3-C-K-FA2. After swelling 0.035 mmol of a fmoc-
Cys(trt)-Wang resin in DCM and cleavage of the fmoc
protecting group (20% piperidine in DMF, twice), 4 equiv of a
solution of fmoc-Stp(boc)3-OH in DMF, DIPEA (8 equiv), and
PyBOP/HOBt (4 equiv) were added to the resin, and the
vessel was agitated until Kaiser test indicated complete
conversion (normally 30 min). The reaction solvent was
drained and the resin was washed five times with DMF. This
cycle was repeated twice. Afterward, the amino acid fmoc-
Cys(trt)-OH was coupled. Then, in order to couple two fatty
acids to the linear PAA, fmoc-Lys(fmoc)-OH was incorporated
at the N-terminus before coupling the fatty acid. To cap
unreacted primary amino groups, the resin was acetylated using
5 equiv of acetic anhydride and 10 equiv of DIPEA, before the
subsequent removal of the fmoc protecting group. To couple
the fatty acid, the solvent was changed to DCM after fmoc
cleavage. Therefore, after removal of the fmoc protecting group,
the resin was washed three times with DMF and DCM. Ten
equivalents of the fatty acid were dissolved in DCM; 20 equiv
of DIPEA, and 10 equiv of PyBOP/HOBt in DMF were added
to the resin; and the mixture was agitated for 30 min. After
completion of the reaction, the resin was washed with DMF,
DCM, and n-hexanes and dried over KOH in vacuo.
Synthesis of T-Shapes with Two FAs: HO-C-Stp1-K(K-
FA2)-Stp1-C. After swelling 0.05−0.20 mmol of fmoc-Cys(trt)-
Wang resin in DCM for 30 min, the fmoc protection group was
cleaved (20% piperidine in DMF, twice). After washing the
resin, 4 equiv of fmoc-Stp(boc)3-OH, DIPEA (8 equiv) and
PyBOP/HOBt (4 equiv) was added for 30 min. The reaction
solvent was drained and the resin was washed five times with
DMF. Reaction progress was monitored by Kaiser test. To
introduce a branching point, dde-Lys(fmoc)-OH was used in
the next coupling step. Dde-Lys(fmoc)-OH (4 equiv), DIPEA
(8 equiv), and PyBOP/HOBt (4 equiv) dissolved in DMF were
added, and the synthesis vessel was agitated for 30 min. After a
negative Kaiser test, the resin was washed with DMF. After
treatment with 20% piperidine in DMF and washing the resin
with DMF, fmoc-Lys(fmoc)-OH (4 equiv), DIPEA (8 equiv),
and PyBOP)/HOBt (4 equiv) were added. In order to cap
unreacted primary amino groups, the resin was acetylated using
5 equiv of acetic anhydride and 10 equiv of DIPEA, before the
subsequent removal of the fmoc protecting group. To couple
the fatty acid, the solvent was changed to DCM after fmoc-
cleavage. Therefore, the resin was washed three times with
DMF and DCM after removal of the fmoc protecting group.
Ten equivalents of the fatty acid dissolved in the minimal
amount of DCM, 20 equiv of DIPEA and 10 equiv of PyBOP/
HOBt were added to the resin for 30 min. After completion of
the reaction, the resin was washed five times with DCM and
three times with DMF. The dde protecting group was cleaved
using 2% hydrazine monohydrate in DMF (10−15 times for 5
min) until no significant A300 was measurable in the
deprotection mixture. After washing the resin 5 times with
DMF, fmoc-Stp(boc)3-OH, DIPEA (8 equiv) and PyBOP/
HOBt (4 equiv) in DMF were added for 30 min. After
successful reaction, the resin was treated twice with 20%
piperidine in DMF. After washing the resin, boc-Cys(trt)-OH
(4 equiv) dissolved in DMF, DIPEA (8 equiv), and PyBOP/
HOBt (4 equiv) were added for 30 min. Afterward, the resin
was washed and dried over KOH in vacuo.
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Cleavage Conditions. For cleavage, the resin was treated
with 10 mL/g(resin) of cleavage solution: PAAs without cysteines
were treated with a TFA/water (95:5) mixture, whereas
cysteine-containing PAAs were treated with a TFA/Water/
TIS (95:2.5:2.5) mixture for 1−2 h. The resin was filtered off
and washed twice using pure TFA followed by one DCM wash.
The combined filtrates were concentrated and either
precipitated by dropwise addition into ice-cold MTBE or
other suitable mixtures. The precipitate was collected by
centrifugation. The precipitate/film was dissolved in 5% acetic
acid, snap-frozen, and lyophilized to obtain the PAA.
DNA Polyplex Formation Using PAA-Based Carriers.
Polyplex formulations for pDNA delivery were prepared as
follows: 200 ng of pDNA/well and the calculated amount of
PAA were diluted in separate tubes in HBG pH 7.4. The pDNA
solution was added to the polymer solution, mixed by pipetting,
and incubated for 30−40 min at RT in order to form the
polyplexes.
Electrophoretic Mobility Shift Assay. A 1% agarose gel
was prepared by dissolving 1.2 g agarose in 120 mL TBE buffer
and heating the mixture to 100 °C. After cooling down to
approximately 50 °C, 120 μL Gel-Red (1 mg/mL) were added
and the gel was poured in a casting unit. Polyplex-samples
containing 200 ng pDNA, polymer, HBG-buffer, and loading
buffer were placed into the pockets after an incubation time of
30 min at RT. Electrophoresis was performed at 120 V for 80
min.
Erythrocyte Leakage Assay. Murine erythrocytes were
isolated from fresh, citrate buffered blood and washed with
phosphate-buffered saline (PBS) several times. The erythrocyte
pellet was diluted to 5 × 107 erythrocytes per mL with PBS
(pH 7.4, 6.5, and 5.5). The polymers were diluted in 75 μL of
PBS in a V-bottom 96-well plate (NUNC, Denmark). For
100% lysis, control wells contained buffer with 1% Triton X-
100. A volume of 75 μL of erythrocyte suspension was added to
each well, and the plates were incubated at 37 °C under
constant shaking for 1 h. After centrifugation, 80 μL of the
supernatant was analyzed for hemoglobin release at 405 nm
using a microplate plate reader (Spectrafluor Plus, Tecan
Austria GmbH, Grödig, Austria). PBS-buffers with pH values of
7.4, 6.5, and 5.5 were used as negative control. Relative
hemolysis was defined as hemolysis (%) = (A405(PAA treated)
− A405(buffer treated))/(A405(TritonX treated − (A405(Buffer
treated)) × 100.
Measurement of Particle Size via Dynamic Light
Scattering. DNA polyplexes were formed as follows: 10 μg
of pEGFPLuc and 100 μg or 200 μg polymer, resulting in a
weight to weight of 10 or 20, respectively, were diluted in
separate tubes in buffer (20 mM HEPES pH 7.4) to a total
volume of 25 μL. The pDNA solution was added to the
polymer solution and mixed by rapidly pipetting up and down
at least 5 times, resulting in a final pDNA concentration of 200
μg/mL. The incubation time was 30−40 min, in order to
complete polyplex formation. The polyplex solution was then
diluted 1:20 with buffer and measured in a folded capillary cell
(DTS1061) with laser light scattering using a Zetasizer Nano
ZS with backscatter detection (Malvern Instruments, Worces-
tershire, UK).
Luciferase Reporter Gene Expression. Cells were plated
in 96-well plates at a density of 10 000 cells/well 24 h prior to
transfection. The polyplexes, formed using 200 ng of pDNA/
well, were added to the cells in 100 μL culture medium
containing 10% serum, 100 U/mL penicillin, and 100 μg/mL
streptomycin. Twenty-four hours after initial transfection,
medium was removed and cells were lysed in 50 μL 0.5×
Promega cell lysis solution to measure the gene expression.
Luciferase activity was measured using a Lumat LB9507
instrument (Berthold, Bad Wildbad, Germany). Luciferase
light units were recorded from a 20 μL aliquot of the cell lysate
with 10 s integration time after automatic injection of freshly
prepared luciferin using the luciferase assay system (LAR,
Promega, Mannheim, Germany). Transfection efficiency was
evaluated as relative light units (RLU) per number of seeded
cells. Two nanograms of recombinant luciferase (Promega,
Mannheim, Germany) corresponded to 107 light units.
Cell Viability Assay. The metabolic activity of polyplex-
treated cells was determined in parallel to the transfection
studies using a methylthiazole tetrazolium (MTT)22 assay.
Twenty-two hours after initiation of transfection, 10 μL per 100
μL of medium of a 5 mg/mL solution of MTT in sterile PBS-
buffer was added per well. After incubation for 1−2 h at 37 °C,
the medium was removed and the cells were frozen at −80 °C
for at least 1 h. 200 μL DMSO were added and the samples
were incubated under constant shaking at 37 °C for 30 min to
dissolve the crystals completely. The optical absorbance was
measured at 590 nm with a reference wavelength of 630 nm
using a microplate reader (Spectrafluor Plus,Tecan Autstria
GmbH, Grödig, Austria). The relative cell viability was defined
as viability (%) = A590(polyplex treated)/A590(Buffer treated
control) × 100.
■ RESULTS AND DISCUSSION
Design and Synthesis of Sequence-Defined Trans-
fection Polymers. A small library of sequence-defined PAAs
was designed with the aim of identifying a set of minimal
prerequisites for efficient pDNA delivery. The design was
limited to three structural motifs: compaction domain,
lipophilic element, and dimerizing/cross-linking anchors. The
compaction domain was introduced by variable repeats of Stp,
an artificial polyamino acid mimicking the diaminoethane motif
of PEI.19 Lipophilic chains of varying length (C4, C8, C14, C18),
anchored to the polymers either via their N-terminus or by
acylation of both amines of a lysine, were used to control the
lipophilicity. Cysteines were introduced to compensate for the
rather small size of the synthesized polymers (Mw ≤ 3100 Da)
and to limit possible polyplex destabilization in serum. The
disulfide bonds formed by oxidation of cysteine thiols have
been reported to stabilize polyplexes in the rather low
extracellular reductive potential and can be reduced in the
cytosol to facilitate pDNA release.23
Figure 1 shows the general structures of the synthesized
polymer families. The exact configuration of the modules was
varied in the different families to allow impact analysis of the
different modules. The simplest structural family is the PAA
chain (structure I), constructed by linear chain elongation
using Stp and/or amino acid units. These polymers,
comparable to OEI800 in Mw and number of protonable
amines, were included as negative controls. The PAA chain
(structure II) contains two cysteine residues, introducing the
ability to form disulfide bridges. Both families were hydro-
phobically modified using fatty acids (FA) at their N-terminus,
resulting in the i-shape families (structures III + IV). The
dimerizing i-shapes (structure V) were synthesized to test
polyplex stabilization using dimerization anchors, whereas the
symmetrical T-shape family (structure VI) was used to
examine the influence of a changed polymer topology on
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transfection efficacy. Scheme 1 shows the general synthetic
procedure using standard fmoc-synthesis conditions. A
branching point was incorporated by using dde-Lys(fmoc)-
OH to introduce a bis-fatty acid modified lysine at the center of
the molecule. After successful side chain deprotection and
introduction of the fatty acid residues, the dde protective group
on the α-amino function was removed by hydrazine treatment
and the synthesis continued. All polymers were cleaved from
the support using a mixture of TFA/H2O or TFA/H2O/TIS
and characterized by 1H NMR. The sequences of all used
polymers can be found in Table 1.
Evaluation of pH-Dependent Lytic Activity. To escape
endosomal entrapment, an effective lytic activity of the carrier is
a desirable prerequisite for successful delivery of nucleic acids
into the cytosol. Potential cytotoxic interactions with cell
membranes in the beginning of the transfection process should
be reduced by using pH-specific lytic delivery systems, thereby
lowering the overall cytotoxic potential of the carrier. The
different polymer families were screened in a mouse
erythrocyte leakage assay system to identify structural motifs,
resulting in lytic activity. All measured values were buffer-
corrected and lysis caused by 1% Triton X-100 was set as 100%.
By testing the polymers at different pH values, comparable to
the pH of different stages of the endosome,24 highly pH-specific
lytic polymers were identified. Figure 2a shows the lytic activity
Figure 1. Structural overview over the different polymer families in the
library. PAA chain (I), PAA chain with cross-linking cysteines (II),
PAA with acylation at N-terminal lysine (i-shape type) without (III),
with one dimerizing (V), or with two cross-linking cysteines (IV);
PAA with acylation in the center (T-shape type) and cross-linking
cysteines (VI).
Scheme 1. Solid-Phase Synthesis Procedure Exemplified by T-Shape Synthesis
Table 1
polymer sequencea
1 K-Stp1-K
6 K-Stp2-K
23 K-Stp5-K
34 K-Stp2-ButA
35 K-Stp2-CapA
36 K-Stp2-MyrA
37 K-Stp2-OleA
8 K-Stp2-K-CapA2
9 K-Stp2-K-MyrA2
10 K-Stp2-K-OleA2
21 K-Stp4-K-MyrA2
22 K-Stp4-K-OleA2
69 C-Stp2-K-MyrA2
70 C-K-Stp2-K-MyrA2
72 C-Stp2-K-OleA2
71 C-K-Stp2-K-OleA2
51 C-Stp3-C-K
45 C-Stp3-C-K-MyrA2
46 C-Stp3-C-K-OleA2
76 C-Stp1-K(K-OleA2)-Stp1-C
49 C-Stp2-K-(K-OleA2)-Stp2-C
80 C-Stp3-K(K-OleA2)-Stp3-C
84 C-Stp4-K(K-OleA2)-Stp4-C
74 C-Stp1-K(K)-Stp1-C
78 C-Stp3-K(K)-Stp3-C
82 C-Stp4-K(K)-Stp4-C
aButA, Butyric acid; CapA, Caprylic acid; MyrA, Myristic acid; OleA,
Oleic acid.
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of a subset of the library at pH 5.5, pH 6.5, and pH 7.4 in PBS.
Lytic activity of the unmodified PAA backbone was assessed by
the model sequences K-Stp1-K (1), K-Stp2-K (6); K-Stp5-K
(23). These plain PAA sequences did not demonstrate any lytic
activity even at concentrations >5 μM (data not shown).
Introduction of a single N-terminal fatty acid into a K-Stp2
sequence (34−37) showed a slight increase in activity with
oleic (37) and myristic acid (36) as the most effective
modifications. In contrast, polymers modified with fatty acids <
C14 (34, 35) were not lytic.
Lytic potency of the polymers was further increased by using
a N-terminal lysine as branching point for two fatty acids
(double fatty acid motif). The increased lytic activity can be
attributed to the close vicinity of the fatty acids resembling the
general structure of amphipathic lipids.25 Acylation of the N-
terminal lysine, using caprylic acid (8), did not result in strong
lytic activity, due to the rather short alkyl chain. Incorporation
of myristyl residues (9), however, resulted in strong, unspecific
lysis already causing up to 40% of erythrocyte rupture at neutral
pH. Oleic acid modification (10) led to moderate, highly pH-
specific lytic activity, rendering this modification the most
valuable. A generally advantageous trend of an increased activity
at lower pH was observed for all PAAs double-modified with
fatty acid. This pH-specificity might be caused by the increased
protonation of the polyamine backbone at the slightly acidic pH
and, thus, increased interaction with negatively charged
domains of the cell membranes. The size of the nucleic acid
binding domain had only moderate effects on lytic activity (21
vs 9, 10 vs 22) and did not influence the pH-dependency. A
plausible explanation is the reduced molar proportion of the
hydrophobic domain in the polymer, indicating that 2−3 Stp
units may be the optimal chain length for specific and high lytic
activity, using polymers with one hydrophobic module. The
introduction of cysteines into the sequence as dimerization/
cross-linking handle did not significantly alter the extent and
pH-specificity of erythrocyte lysis (9, 10 vs 70, 71 and 45, 46).
The position of the hydrophobic element had no significant
influence on the specificity of lytic activity, when comparing
oleic acid modified i-shapes and T-shapes (45 vs 76). However,
with increasing molecular weight of the T-shapes (76, 49, 80,
84) an increase in general lytic potency was observed. This is
probably connected to a stronger interaction of the polymers
with the negatively charged cell membrane. The corresponding
control polymers (74, 78, 82) without fatty acid modification
demonstrated no lytic activity, confirming the need of
hydrophobic modification for lytic cell membrane interaction.
The results clearly demonstrate that the lytic activity of the
polymers can be controlled by their molecular structure,
especially by the substitution pattern and type of fatty acids
used. Whereas unmodified PAAs demonstrated no lytic activity,
introduction of fatty acids with a chain length of > C8 resulted
in significant lytic activity. This was amplified by the use of a
double fatty acid motif. The pH-specificity of the lytic activity
was controlled by the type of fatty acid used. Oleic acid
modification resulted in the most specific lytic activity of the
tested polymers.
DNA Binding. The interaction of the polymers with pDNA
was evaluated using an agarose gel shift assay (Figure 3), in
which binding strength correlates to the amount of polymer
needed for complete pDNA retardation. Polymers with only
Stp and terminal lysines were not able to inhibit pDNA
migration at the tested concentrations (1, 23). To identify a
minimal binding motif, the short K-Stp2 sequence was modified
either with a single N-terminal fatty acid (35−37) or the
double fatty acid modified lysine motif (8−10), which were
already used to increase the lytic activity. Single N-terminal
fatty acid modification of the polymers resulted only in the case
of oleic acid (37) in some, however, weak pDNA interaction at
w/w 15 (N/P = 21). Introduction of a second fatty acid via a
lysine branching point significantly improved interaction with
pDNA. The dual fatty acid motif displayed strong pDNA/
polymer interactions with almost complete pDNA retardation
at a w/w of 10 (8−10, N/P = 11) if the fatty acid was either
C14 (9) or C18 (10). Use of a C8 (8) modification did not result
Figure 2. Relative pH-dependent lytic activity of the polymer library
(5 μM). All values are buffer corrected; 1% Triton-X 100 was used as
positive control. (a) Non-thiol-containing polymers. (b) Thiol-
containing polymers.
Figure 3. Electrophoretic mobility shift assay of different PAA/pDNA
complexes in HBG at different w/w ratios.
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in pDNA retardation at the tested concentrations. These results
were reflected by DLS-measurements (Figure 4). Thus, neither
the double C8 (8) modified nor the single C14 (36) modified
polymer were able to form stable polyplexes. However, particle
formation was observed with unmodified polymer 23 (17
protonable nitrogens). These polyplexes were characterized by
a size of more than 400 nm and a zeta potential of +15 mV,
supporting the hypothesis of rather weak interactions between
polymer and pDNA, as observed in the gel-shift assay. The
introduction of two cysteines into the polymers (45, 46, 51)
showed only a moderate effect on polyplex stabilization in the
gel shift assay. Polymer 51 containing 3 Stp units and 2
cysteines displayed incomplete pDNA retardation, whereas the
fatty acid modified dimerizing polymers (45, 46) were able to
efficiently complex the pDNA at w/w ratios of 5 (N/P = 5).
Only polymers containing 6 or more Stp units and cysteine
modifications (78, 82, Supporting Information) showed
comparable interaction with pDNA. The stabilizing effect of
cysteine incorporation could also be observed in DLS
measurements (Figure 4; 46, 72). The resulting polyplexes
had a size below 200 nm and a zeta potential around +30 mV,
irrespective of modification with one (72) or two cysteines
(46).
Taken together, these results showed that polyplex
stabilization was controlled by all three used motifs. Hydro-
phobic modification played a key role in lytic activity, but it had
only supporting function in stabilizing the polyplex. By
contrast, size of compaction domain (number of charges) and
stabilization by disulfide bridging or cross-linking had a more
pronounced influence on particle formation. This allowed
tailoring of polymer/DNA interaction strength, which
supported the formation of stable particles in the extracellular
environment and their efficient disassembly in the cytosol.
Transfection Efficiency and Cytotoxicity. The trans-
fection efficiency of the different polymers was assessed in vitro,
using Neuro2A cells and employing a pEGFPLuc reporter gene
system. Linear polyethylenimine 22 kDa (LPEI 22 kDa) was
used as control at its optimal w/w ratio of 0.8 (N/P = 6) to
allow comparison of the different polymers. Due to the small
size (1−3 kDa) of the screened polymers, property changes due
to an altered polymer sequence were reflected in transfection
efficiency and cytotoxicity, allowing quick assessment of the
potential benefit of a modification.
To assess their delivery capability and toxicity, plain PAA
chains and fatty acid modified sequences (i-shapes) were
compared to K-Stp5-K (23). This sequence resembles OEI800, a
rather weak performing member of the PEI family, in terms of
Mw and number of protonable amines. As shown in Figure 5a,
even the use of relatively high polymer concentrations (w/w 20,
N/P = 32) displayed no significant increase of luciferase
expression compared to untreated cells. One reason might be
the inferior condensation properties of plain PAA sequences
compared to the fatty acid modified PAAs (Figure 4, 23), as
well as the absence of lytic activity in the leakage assay (activity
<10% at all pH values). The synergistic effect of polyplex
stabilization and lytic activity was reflected in the reporter gene
expression profiles of all fatty acid modified polymers.
Modification of a K-Stp2-K sequence with either myristic (9)
or oleic acid (10) increased the transfection compared to K-
Stp5-K (23) 10-fold at w/w 10 (N/P = 11). Elongation of the
chain by two additional Stp units (21 and 22) resulted in an up
to 100-fold increase of reporter gene expression. This was
accompanied by a moderate increase in cytotoxicity for the
myristic acid derivatives in all tested concentrations (9 and 21).
Oleic acid modification had a comparable effect on transfection
efficiency, whereas the toxicity of the polymers in the tested
concentration range was negligible (10 and 22). Compared to
the LPEI control, all polymers showed a 1000-fold lower
transfection activity, but demonstrated the beneficial influence
of hydrophobic modifications on polyplex stability and gene
delivery.
To study the influence of a dimerization handle on
transfection efficiency, a single C-terminal cysteine was
introduced into i-shape sequences (69−72). The introduction
of the C-terminal cysteine into fatty acid bearing polymers
showed no significant impact on pDNA complexation, as a w/w
of 10 (N/P = 10−11) was still sufficient for complete
retardation (see Supporting Information). However, using
these dimerizable, fatty acid modified PAAs for pDNA delivery
had a significant effect on reporter gene expression. In
comparison to their analogous sequences K-Stp2-K-MyrA2 (9)
and K-Stp2-K-OleA2 (10), the cysteine containing polymers
(69 and 71) demonstrated a 100-fold increased reporter gene
expression at a w/w of 10 (N/P = 10−11). To evaluate the
possible influence of the primary amine of the lysine residue on
pDNA delivery, sequences without the lysine were screened.
Whereas the lysine had no significant effect on the oleic acid
modified PAAs (72 vs 71), the delivery efficiency of 69
compared to 70 was increased 100-fold. Oleic acid modification
had no pronounced effect on cell viability, regardless of
sequence composition. C-terminal cysteine modification
seemed to be a viable option to increase the delivery capability
of short-chain PAAs, a theory which was additionally supported
by the results of DLS-measurements (Figure 4), demonstrating
the increased stability of cysteine containing polyplexes. These
results supported the hypothesis that PAA polymers without
the ability of disulfide bridge formation suffer from inadequate
stabilization of the resulting polyplexes.
By insertion of a second cysteine into the sequence, the
polymers gained the ability of in situ polymerization, allowing
the formation of larger polymeric structures. Gel retardation
assay (see Supporting Information) showed that in comparison
with single cysteine modified PAAs the pDNA complexation
was improved, but still heavily dependent on hydrophobic
modifications. Figure 5b (45, 46, 51) showed the reporter gene
expression of the cross-linking i-shape formulations with
Figure 4. Particle size and zeta potential of selected examples out of
the different PAA families, formed in HEPES buffer at different w/w
ratios (bars represent the measured particle size, rhombi the measured
zeta potential).
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different fatty acid modifications on a C-Stp3-C-K backbone.
The polymers were able to effectively transfer pDNA into target
cells and showed a transgene expression profile characterized by
a plateau phase beginning at w/w 10 (N/P = 11−15). As soon
as this concentration was reached, reporter gene expression was
not increased by higher polymer concentrations. For other
polymeric delivery systems, this effect was normally connected
to increased cytotoxicity at higher polymer concentrations,
resulting in reduced transfection levels. In the case of the PAA
systems, the MTT assay did not show toxic side effects,
indicating additional intracellular delivery bottlenecks. The
myristic and oleic acid modified i-shapes were able to compete
with the LPEI control in terms of luciferase expression,
demonstrating the delivery potential of these structures. The
use of the backbone control polymer (51) resulted in a 10- to
50-fold lower efficiency, highlighting the importance of the
hydrophobic modification.
By synthesizing a set of symmetrical polymers with a fixed,
central hydrophobic domain (T-shapes), the influence of
parameters, like the amount of protonable groups per molecule
Figure 5. Luciferase reporter gene expression and metabolic activity in Neuro2a cells 24 h after transfection. Polyplexes were formed at different w/w
ratios (polymer/DNA); the LPEI control was always used at its optimal w/w of 0.8 (N/P = 6).
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and hydrophilic−lipophilic ratio, were studied. All tested
polymers were modified with a dual oleic acid motif at the
central lysine, as oleic acid modification was the most effective
modification in terms of toxicity and efficiency in previous
experiments. Figure 5c (compounds 49−84) shows a
comparison between dioleoyl modified T-shapes (76, 49, 80,
84) and not hydrophobically modified linear chains with
terminal cysteines (74, 78, 82). The oleoyl T-shape/pDNA
complexes were strong enough to prevent migration in the gel
at a w/w of 10 (N/P = 9−13), whereas the interaction of the
unmodified chains at the same w/w (N/P = 13−15) was not
strong enough to prevent NA migration (see Supporting
Information). Figure 5c shows the transfection efficiency and
cytotoxic potential of oleoyl T-shapes with different numbers of
Stp building blocks per molecule. The balance between
hydrophobic and cationic domain had a significant impact on
efficacy, as seen by comparing the transfection efficiency of 49
and 76. Whereas increasing concentrations of 76 led to reporter
gene expression almost comparable with the LPEI control, the
use of a polymer containing two additional Stp units resulted in
an early, only moderate, plateau of activity. The introduction of
additional Stp units did not improve their overall performance,
regardless of tested concentrations. The reporter gene
expression was always 10-fold lower than the LPEI control.
These results indicated a fine balance between hydrophobicity
and hydrophilicity as exemplified by 76. Compound 76 had the
highest molar proportion of fatty acid substitution in the screen
and exhibited the strongest activity in terms of expression level.
All other T-shape derivatives could not compete in terms of
expression level and reached their maximum level at lower
concentrations of w/w 5 (N/P = 6−7).
To verify the importance of the hydrophobic domain and to
study the influence of polymer chain length on the efficiency of
the T-shape polymers in more detail, a second set of polymers
with increasing number of monomer units and without
hydrophobic modification (but with cross-linking cysteines)
was synthesized and screened (74, 78, 82). Here, the trend of
chain length influence was reversed. Compound 74, a structural
analogue of 76, did not show any reporter gene expression,
whereas an increase in Stp-building blocks per molecule did
result in an increasing gene expression (78, 82). Compared to
the gene expression levels of the oleoyl T-shapes, these
polymers had the disadvantage of requiring rather high polymer
concentrations to achieve comparable transfection efficiency.
The dual fatty acid motif could increase the delivery efficiency,
but the influence of the modification diminished with an
increasing number of Stp units in the backbone. This supports
earlier findings that the hydrophobic modification was more
effective on smaller PAAs and could increase their efficiency
dramatically, whereas an increasing amount of Stp units in a
fatty acid-free polymer also resulted in an improved, but still
less efficient delivery.
■ CONCLUSIONS
In this study, we successfully designed and synthesized a small
library of sequence-defined polymers with optimized pH-
dependent lytic activity, pDNA binding, and bioresponsive
cargo release. Using a solid-phase assisted synthesis approach
and a small set of different modules, we were able to construct
sequence-defined, multifunctional polymers. Despite the small
size (Mw 500−3100 Da) of the polymers, the library screen
identified several polymers with a pDNA transfection efficiency
comparable to LPEI. The polymers and the synthetic approach
could be seen as model systems to increase the knowledge
about the rational design of polymeric nonviral vectors and will
ultimately lead to even more sophisticated, programmable
polymeric vectors.
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